Biotech benefits

Evaluation of the acute toxicity of theoredoxin (TRX) transgenic soybean to Daphnia magna

This paper is relevant to the impact areas in the following areas:


Abstract or Summary

Theoredoxin (TRX) transgenic soybeans were developed using the human Theoredoxin gene under the control of the β-conglycinin promoter with a selection marker, the phosphinothricin acetyltransferase (PAT) gene. This study was done to assess the acute toxicity of a genetically modified (GM) soybean using the fresh water planktonic crustacean Daphnia magna. The acute toxicity effect of the TRX soybean and non-GM soybean (Gwangan) on D. magna was investigated at different concentrations (0, 156, 313, 625, 1,250, 2,500, and 5,000 mg·L-1). The TRX soybean used for the test was confirmed to express the TRX/PAT genes by PCR and enzyme-linked immunosorbent assay (ELISA). D. magna feeding tests showed no significant differences in the cumulative immobility or an abnormal response with either the TRX soybean or non-GM soybean. The feeding study showed a similar abnormal response and cumulative immobility of the D. magna between the TRX soybean and Gwangan treatments. Additionally, the 48 h-EC50 values for the TRX and Gwangan soybeans were 755.6 and 778 mg·L-1, respectively. The soybean NOEC (no observed effect concentration) value for D. magna was suggested to be 156 mg·L-1. These results suggest that there is no significant difference in toxicity to Daphnia magna between the TRX soybean and its non-GM counterpart.


Evaluation of the acute toxicity of theoredoxin (TRX) transgenic soybean to Daphnia magna (held on an external server, and so may require additional authentication details)

CropLife International fully acknowledges the source and authors of the publication as detailed above.